221 related articles for article (PubMed ID: 25517307)
1. Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody.
Kasai N; Yoshikawa Y; Enokizono J
MAbs; 2014; 6(5):1220-8. PubMed ID: 25517307
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Pharmacokinetics Evaluation of Anti-heparin-binding EGF-like Growth Factor (HB-EGF) Monoclonal Antibody Using Cynomolgus Monkeys via (89)Zr-immuno-PET Study and the Determination of Drug Concentrations in Serum and Cerebrospinal Fluid.
Kasai N; Adachi M; Yamano K
Pharm Res; 2016 Feb; 33(2):476-86. PubMed ID: 26464296
[TBL] [Abstract][Full Text] [Related]
3. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
[TBL] [Abstract][Full Text] [Related]
4. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.
Sarantopoulos J; Mita MM; Birrer MJ; Cranmer LD; Campos LT; Zhang X; Bristow P; Kaito H; Strout V; Camacho LH
Target Oncol; 2016 Jun; 11(3):317-27. PubMed ID: 26507836
[TBL] [Abstract][Full Text] [Related]
6. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a Novel Anti-Human HB-EGF Monoclonal Antibody Applicable for Paraffin-Embedded Tissues and Diagnosis of HB-EGF-Related Cancers.
Iwamoto R; Takagi M; Akatsuka J; Ono K; Kishi Y; Mekada E
Monoclon Antib Immunodiagn Immunother; 2016 Apr; 35(2):73-82. PubMed ID: 26974561
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
9. Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody.
Amano J; Masuyama N; Hirota Y; Tanaka Y; Igawa Y; Shiokawa R; Okutani T; Miyayama T; Nanami M; Ishigai M
Drug Metab Dispos; 2010 Dec; 38(12):2339-46. PubMed ID: 20823293
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
Kelley SK; Gelzleichter T; Xie D; Lee WP; Darbonne WC; Qureshi F; Kissler K; Oflazoglu E; Grewal IS
Br J Pharmacol; 2006 Aug; 148(8):1116-23. PubMed ID: 16847437
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro evidence suggest that HB-EGF regulates endometrial expression of human decay-accelerating factor.
Young SL; Lessey BA; Fritz MA; Meyer WR; Murray MJ; Speckman PL; Nowicki BJ
J Clin Endocrinol Metab; 2002 Mar; 87(3):1368-75. PubMed ID: 11889210
[TBL] [Abstract][Full Text] [Related]
12. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
Sato S; Drake AW; Tsuji I; Fan J
PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative and apoptotic effects of anti-human HB-EGF neutralizing polyclonal antibodies in vitro.
Siromolot AA; Krynina OI; Kolybo DV; Komisarenko SV
Exp Oncol; 2020 Mar; 42(1):25-30. PubMed ID: 32231194
[TBL] [Abstract][Full Text] [Related]
14. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods.
Tsuji I; Sato S; Otake K; Watanabe T; Kamada H; Kurokawa T
MAbs; 2012; 4(6):732-9. PubMed ID: 23007682
[TBL] [Abstract][Full Text] [Related]
16. Membrane type 1-matrix metalloproteinase cleaves off the NH2-terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor.
Koshikawa N; Mizushima H; Minegishi T; Iwamoto R; Mekada E; Seiki M
Cancer Res; 2010 Jul; 70(14):6093-103. PubMed ID: 20587521
[TBL] [Abstract][Full Text] [Related]
17. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation.
Di Simone N; Marana R; Castellani R; Di Nicuolo F; D'Alessio MC; Raschi E; Borghi MO; Chen PP; Sanguinetti M; Caruso A; Meroni PL
Arthritis Rheum; 2010 May; 62(5):1504-12. PubMed ID: 20131286
[TBL] [Abstract][Full Text] [Related]
19. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
20. Anti-HB-EGF Antibody-Mediated Delivery of siRNA to Atherosclerotic Lesions in Mice.
Tsuchida S; Matsuzaki T; Yamato M; Okuda K; Fu HY; Araki R; Sanada S; Asanuma H; Asano Y; Asakura M; Hao H; Takashima S; Kitakaze M; Sakata Y; Mekada E; Minamino T
Int Heart J; 2018 Nov; 59(6):1425-1431. PubMed ID: 30393262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
